ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Active ETF
    • Alternatives
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Disruptive Technology
    • Dividend
    • Dual Impact
    • Emerging Markets
    • Energy Infrastructure
    • ESG
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Fixed Income
    • Free Cash Flow
    • Future ETFs
    • Global Diversification
    • Gold/Silver/Critical Minerals
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Market Insights
    • Megatrends
    • Modern Alpha
    • Multi-Asset
    • Night Effect
    • Portfolio Strategies
    • Retirement Income
    • Richard Bernstein Advisors
    • Tax Efficient Income
    • Thematic Investing
    • Volatility Resource
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
    • ETF Data for Journalists
    • ETF Nerds
  • Research
    • First Bitcoin ETF
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Multimedia
    • ETF 360 Video Series
    • ETF Trends on Videos
    • ETF Trends on Podcasts
    • ETF Prime Podcast
  • Company
    • About Us
    • Swag Store
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Beyond Basic Beta Channel
  2. ETFs Can Deal With Drug Pricing Legislation
Beyond Basic Beta Channel
Share

ETFs Can Deal With Drug Pricing Legislation

Tom LydonJul 27, 2022
2022-07-27

This is a mid-term election year, meaning that some familiar issues investors should be aware of are popping up yet again. That includes reducing pharmaceutical prices.

Market participants may view the reappearance of the drug price debate as ill-timed on the basis that the healthcare sector is struggling this year, but some analysts believe that blue-chip pharmaceuticals companies, including components of the VanEck Vectors Pharmaceutical ETF (PPH A-), can handle the specter of lower drug prices.

That’s potentially good news because PPH, which tracks the MVIS US Listed Pharmaceutical 25 Index, is home to plenty of stocks that could be vulnerable to negative market reactions to lower drug prices. To its credit, PPH has been mostly sturdy following Senate Democrats recently unveiling a plan that, if signed into law, would allow Medicare to negotiate reduced pharmaceuticals prices.

Under the terms of the proposal, the Department of Health and Human Services (HHS) would be able to, starting in 2026, select 10 drugs from the top 50 in Medicare parts B and D on which to lower prices. Another 20 drugs could be added three years later.

“The discount is based on how long the drug has been on the market. For drugs marketed more than nine years, a minimum 25% discount is required; greater than 12 years, 35%; and greater than 16 years, 60%,” according to Seeking Alpha.

Obviously, this is a relevant development to PPH’s 26 components, which include Eli Lilly (NYSE:LLY), Dow components Merck (NYSE:MRK) and Johnson & Johnson (NYSE:JNJ), Pfizer (NYSE:PFE), and Bristol-Meyers Squibb (NYSE:BMY), among others.

Drugs produced by those companies and other PPH member firms are among the most prescribed to Medicare recipients, confirming that investors considering PPH should stay abreast of these negotiations. However, recent developments don’t necessarily mean PPH holdings are in for downside. As noted above, the Senate proposal pertains to Medicare recipients — not the entire audience to which pharmaceuticals are prescribed.

Additionally, with the mid-term elections right around the corner, near-term action on the aforementioned legislation may not occur. Some analysts say that PPH member firms have avenues to deal with the Senate proposal.

“Our analysis indicates that companies are already beginning to accelerate their rate of price increases, perhaps in part due to inflationary factors but potentially also due to anticipation of the legislation and its possible long-term impact,” according to RBC analysts.

For more news, information, and strategy, visit the Beyond Basic Beta Channel.

Loading Articles...
Help & Info
  • Contact Us
Tools
  • ETF Screener
  • ETF Analyzer
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Performance Visualizer
  • ETF Database Model Portfolios
  • ETF Database Realtime Ratings
  • ETF Database Pro
More Tools
  • ETF Launch Center
  • Financial Advisor & RIA Center
  • ETF Database RSS Feed
Explore ETFs
  • ETF News
  • ETF Picks of the Month
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Best ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Legal
  • Terms of Use and Privacy Policy
  • © 2023 VettaFi LLC. All rights reserved.
Follow ETF Database
Follow ETF Database

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X